HEMOSTASIS COAGULATION ROUTINE REAGENTS THROMBOPHILIA FACTOR V LEIDEN / APCR
CRYOcheck™ APCR Positive Control
Heterozygous control for the validation of the assay of resistance to protein C activated by the coagulant method in hemostasis.
Quality control plasmas are collected from a donor confirmed heterozygous for the Factor V Leiden mutation by molecular biology and not having anticoagulant therapy.
Informations
Resistance to activated protein C (RPCa) is an anomaly described by Dahlbäck in 1993.
Bertina discovered in 1994 the presence of a mutation in the factor V (FV) gene.
This mutation leads to the replacement at position 506 of an arginine by a glutamine (Arg506Gln), which affects one of the sites of cleavage of FV by PCa.
As a result, FV "resists" inactivation by PCa. The mutated FV is referred to as FV Leiden. This factor V loses its function as a cofactor of the protein C system, that is to say of a system which inhibits coagulation; on the other hand, it retains its procoagulant properties. There are other cases of mutations related to the resistance of activated protein C.
Documentation
Download the product sheetPrice list, safety data sheets and notices are accessible to our registered customers.
Chronometric assay
References
| APCR-05 | Kit | 25 x 0.5 mL |
